Foundation Fighting Blindness Retinal Degeneration Fund

CIK: 0002042266

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (75.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)0 (0.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (25.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

IRD

Opus Genetics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (4 total)

IRD
Opus Genetics, Inc.
Sep 30, 2026
Sale(S)
Direct
556K shares at avg. $4.96$2.8M
IRD
Opus Genetics, Inc.
May 18, 2026
Sale(S)
Direct
1.7M shares at avg. $4.35$7.4M
IRD
Opus Genetics, Inc.
Dec 9, 2025
Sale(S)
Direct
4M shares at avg. $2.15$8.6M
IRD
Opus Genetics, Inc.
May 5, 2025
Conversion(C)
Direct
6.9M shares-

		Type	Shares	Price		Ownership
Sep 30, 2026	IRD Opus Genetics, Inc.	Sale(S)	556,000	$4.96	$2,755,981	Direct
May 18, 2026	IRD Opus Genetics, Inc.	Sale(S)	1,700,000	$4.35	$7,395,000	Direct
Dec 9, 2025	IRD Opus Genetics, Inc.	Sale(S)	4,000,000	$2.15	$8,600,000	Direct
May 5, 2025	IRD Opus Genetics, Inc.	Conversion(C)	6,927,419	-	-	Direct

1-4 of 4 transactions

About Foundation Fighting Blindness Retinal Degeneration Fund

Foundation Fighting Blindness Retinal Degeneration Fund (SEC CIK 0002042266) files insider reports with the SEC as Director of Opus Genetics, Inc. (IRD).

Signal8 holds 5 ownership filings by Foundation Fighting Blindness Retinal Degeneration Fund (1 Form 3, 4 Form 4), filed between Oct 29, 2024 and Oct 2, 2026. Those filings report 4 transactions, from May 5, 2025 to Sep 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Foundation Fighting Blindness Retinal Degeneration Fund's filings is in RALEIGH, NC.

Recent filings by Foundation Fighting Blindness Retinal Degeneration Fund

Sep 30, 2026: Open-market sale of IRD shares (Form 4, code S).
May 18, 2026: Open-market sale of IRD shares (Form 4, code S).
Dec 9, 2025: Open-market sale of IRD shares (Form 4, code S).
May 5, 2025: Conversion of IRD shares (Form 4, code C).

Other insiders filing for Opus Genetics, Inc. (IRD)

SCHACHLE JOSEPH K, Chief Operating Officer
YERXA BENJAMIN R, President
Gagnon Robert E., Chief Financial Officer
Magrath George, Chief Executive Officer
Gallagher Cam, Director
Zaremba Rabourn Amy, Head of Fin. Quality Assurance

How to read Form 4 transaction codes